Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future

Mucopolysaccharidosis type II (MPS II; Hunter syndrome; OMIM 309900) is a rare, multisystemic, progressive lysosomal storage disease caused by deficient activity of the iduronate-2-sulfatase (I2S) enzyme. Accumulation of the glycosaminoglycans dermatan sulfate and heparan sulfate results in a broad...

Descripción completa

Detalles Bibliográficos
Autores principales: Whiteman, David AH, Kimura, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574592/
https://www.ncbi.nlm.nih.gov/pubmed/28860717
http://dx.doi.org/10.2147/DDDT.S139601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574592/
https://www.ncbi.nlm.nih.gov/pubmed/28860717
http://dx.doi.org/10.2147/DDDT.S139601

Ejemplares similares